ACRV Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 17:30):

Stats
Dzisiejszy wolumen	10 852.00
Średni wolumen	787 779
Kapitalizacja rynkowa	272.80M
EPS	$0 ( 2024-05-14 )
Następna data zysków	( $-0.590 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.06
ATR14	$0.0540 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Peterson Katharine	Sell	99	Common Stock
2024-05-14	Miller Mary	Sell	184	Common Stock
2024-05-14	Masson Kristina	Sell	490	Common Stock
2024-05-14	Holm-jorgensen Rasmus	Sell	368	Common Stock
2024-05-14	Gamelin Erick	Sell	402	Common Stock

INSIDER POWER
24.56
Last 67 transactions
Buy: 13 025 326 \| Sell: 16 703 897

Wolumen Korelacja

Długi: 0.15 (neutral)

Krótki: 0.18 (neutral)

Signal:(49.946) Neutral

Acrivon Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acrivon Therapeutics, Korelacja - Waluta/Towar

0.05
( neutral )

0.31
( neutral )

0.00
( neutral )

0.24
( neutral )

0.36
( neutral )

0.30
( neutral )

Acrivon Therapeutics, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-536 000 (0.00 %)
EPS:	$-2.74

FY	2023
Przychody:	$0
Zysk brutto:	$-536 000 (0.00 %)
EPS:	$-2.74

FY	2022
Przychody:	$0
Zysk brutto:	$-1.10M (0.00 %)
EPS:	$-1.350

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.260

Financial Reports:

No articles found.

Acrivon Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acrivon Therapeutics,

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.